Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
111 hedge funds and large institutions have $539M invested in Insys Therapeutics, Inc. in 2014 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 40 increasing their positions, 32 reducing their positions, and 16 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
75% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 16
53% more capital invested
Capital invested by funds: $352M → $539M (+$187M)
25% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 32
12% more funds holding
Funds holding: 99 → 111 (+12)
0% more call options, than puts
Call options by funds: $8.81M | Put options by funds: $8.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$23.1M |
| 2 |
Millennium Management
New York
|
+$20.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15.9M |
| 4 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$14.9M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$10M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$10.4M |
| 2 |
BTP
Bloom Tree Partners
New York
|
-$7.85M |
| 3 |
BG
BlackRock Group
London,
United Kingdom
|
-$6.36M |
| 4 |
PP
PDT Partners
New York
|
-$5.22M |
| 5 |
Morgan Stanley
New York
|
-$3.52M |
INSY Hedge Fund Activity: Q3 2014 in Review
111 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q3 2014, worth a combined $539M — up 53% from $352M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new INSY positions and 16 closed out — a net gain of 12 holders — while 40 added to existing stakes and 32 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $23.1M. The largest seller was BlackRock Advisors, cutting an estimated $10.4M.
- 111 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q3 2014, up from 99 in Q2 2014.
- Funds reported $539M of Insys Therapeutics, Inc. stock for Q3 2014, up 53% quarter-over-quarter.
- 28 funds opened new Insys Therapeutics, Inc. positions in Q3 2014 and 16 closed out, a net change of +12 holders.
- The largest Insys Therapeutics, Inc. buyer in Q3 2014 was OrbiMed, an estimated $23.1M added.
- The largest Insys Therapeutics, Inc. seller in Q3 2014 was BlackRock Advisors, an estimated $10.4M sold.
Based on aggregated 13F filings for Q3 2014.